Chemryt - We contribute to the Chemicals, Pharmaceutical & Biotech industry using information technology

C28H19N3O5ClIS2 | Cheminformatics

(4E)-1-[5-[(2-chlorophenyl)methylsulfanyl]-1,3,4-thiadiazol-2-yl]-4-[2,3-dihydro-1,4-benzodioxin-6-yl(hydroxy)methylidene]-5-(4-iodophenyl)pyrrolidine-2,3-dione

Molecular Formula : C28H19N3O5ClIS2 | Mutagenic : none | Tumorigenic : none | Reproductive Effective : high |
(4E)-1-[5-[(2-chlorophenyl)methylsulfanyl]-1,3,4-thiadiazol-2-yl]-4-[2,3-dihydro-1,4-benzodioxin-6-yl(hydroxy)methylidene]-5-(4-iodophenyl)pyrrolidine-2,3-dione is not a drug-like molecule.

MolName : (4E)-1-[5-[(2-chlorophenyl)methylsulfanyl]-1,3,4-thiadiazol-2-yl]-4-[2,3-dihydro-1,4-benzodioxin-6-yl(hydroxy)methylidene]-5-(4-iodophenyl)pyrrolidine-2,3-dione

MolecularFormula : C28H19N3O5ClIS2

Smiles : O/C(/c(cc1)cc2c1OCCO2)=C(\C(c(cc1)ccc1I)N(C1=O)c2nnc(SCc(cccc3)c3Cl)s2)/C1=O

InChI : InChI=1S/C28H19ClIN3O5S2/c29-19-4-2-1-3-17(19)14-39-28-32-31-27(40-28)33-23(15-5-8-18(30)9-6-15)22(25(35)26(33)36)24(34)16-7-10-20-21(13-16)38-12-11-37-20/h1-10,13,23,34H,11-12,14H2/t23-/m1/s1

InChIK : AQLQMOZHXGTYIG-HSZRJFAPSA-N

TotalMolweight : 703.96

Molweight : 703.96

MonoisotopicMass : 702.949937

CLogP : 5.7553

CLogS : -8.135

H Acceptors : 8

H Donors : 1

TotalSurfaceArea : 427.04

Relative PSA : 0.28691

PolarSurfaceArea : 155.39

Druglikeness : -5.3717

Mutagenic : none

Tumorigenic : none

Reproductive Effective : high

Irritant : none

Nasty Functions :

Shape Index : 0.475

Fragments : 1

Non HAtoms : 40

NonCHAtoms : 12

Electronegative Atoms : 12

StereoCenters : 1

Rotatable Bond : 6

Rings Closures : 6

Small Rings : 6

Aromatic Rings : 4

Aromatic Atoms : 23

Sp3Atoms : 8

Symmetricatoms : 2

Amides : 1

Aromatic Nitrogens : 2

StereoCon : racemate

Request More Details | (4E)-1-[5-[(2-chlorophenyl)methylsulfanyl]-1,3,4-thiadiazol-2-yl]-4-[2,3-dihydro-1,4-benzodioxin-6-yl(hydroxy)methylidene]-5-(4-iodophenyl)pyrrolidine-2,3-dione


SKU Product Name Product Unit Qty Supplier Email
User Name
User Email
Additional Comments